NeuroBo Pharmaceuticals Inc. (NRBO): Price and Financial Metrics
GET POWR RATINGS... FREE!
NRBO Stock Price Chart Interactive Chart >
NRBO Price/Volume Stats
|Current price||$0.79||52-week high||$63.85|
|Prev. close||$0.81||52-week low||$0.55|
|Day high||$0.81||Avg. volume||1,592,188|
|50-day MA||$1.11||Dividend yield||N/A|
|200-day MA||$10.43||Market Cap||5.14M|
NeuroBo Pharmaceuticals Inc. (NRBO) Company Bio
NeuroBo Pharmaceuticals Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals conducts business in the United States.
Most Popular Stories View All
NRBO Latest News Stream
|Loading, please wait...|
NRBO Latest Social Stream
View Full NRBO Social Stream
Latest NRBO News From Around the Web
Below are the latest news stories about NEUROBO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate NRBO as an investment opportunity.
The trading week is almost complete but we've still got the biggest pre-market stock movers to go over for Friday morning!
It's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Thursday!
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!
We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning!
NEUROBO ANNOUNCES CLOSING OF $32.3 MILLION UNDERWRITTEN PUBLIC OFFERING INCLUDING FULL EXERCISE OF OVERALLOTMENT OPTION AND CONCURRENT PRIVATE PLACEMENT
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) ("NeuroBo" or the "Company"), a clinical-stage biotechnology company focused on therapies for cardiometabolic diseases, today announced the closing of an underwritten public offering of units with gross proceeds of approximately $17.3 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by
NRBO Price Returns